<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708782</url>
  </required_header>
  <id_info>
    <org_study_id>RIN-PF-301</org_study_id>
    <nct_id>NCT04708782</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>TETON</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study RIN-PF-301 is designed to evaluate the safety and efficacy of inhaled treprostinil in&#xD;
      subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the safety and efficacy of inhaled treprostinil in subjects with IPF over a 52-week&#xD;
      period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo.&#xD;
      All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths&#xD;
      administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths&#xD;
      QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum&#xD;
      clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic&#xD;
      will be required at Weeks 4, 8, 16, 28, 40, and 52.&#xD;
&#xD;
      Efficacy assessments include spirometry (forced vital capacity [FVC]), time to clinical&#xD;
      worsening, time to first acute exacerbation of IPF, overall survival, King's Brief&#xD;
      Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic&#xD;
      peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity&#xD;
      (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse&#xD;
      events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG)&#xD;
      parameters.&#xD;
&#xD;
      Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label&#xD;
      extension (OLE) study after completing the final study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Absolute FVC from Baseline to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Worsening</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Acute Exacerbation of IPF</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>An exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Vital status will be assessed for all subjects at Week 52, including those who discontinue the study prematurely or who withdraw consent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in % Predicted FVC from Baseline to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in K-BILD Questionnaire Score from Baseline to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The K-BILD is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo inhaled using an ultrasonic nebulizer QID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Treprostinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered QID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Treprostinil</intervention_name>
    <description>Inhaled treprostinil (6 mcg/breath) administered QID</description>
    <arm_group_label>Inhaled Treprostinil</arm_group_label>
    <other_name>Tyvaso</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treprostinil Ultrasonic Nebulizer</intervention_name>
    <description>Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.</description>
    <arm_group_label>Inhaled Treprostinil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject gives voluntary informed consent to participate in the study.&#xD;
&#xD;
          2. Subject is ≥40 years of age, inclusive, at the time of signing informed consent.&#xD;
&#xD;
          3. The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical&#xD;
             Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution&#xD;
             computed tomography (HRCT) (performed within the previous 12 months), and if&#xD;
             available, surgical lung biopsy.&#xD;
&#xD;
          4. FVC ≥45% and ≤80% predicted at Screening.&#xD;
&#xD;
          5. Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for ≥30&#xD;
             days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not&#xD;
             permitted.&#xD;
&#xD;
          6. Women of childbearing potential must be non-pregnant (as confirmed by a urine&#xD;
             pregnancy test at Screening and Baseline) and non-lactating, and will abstain from&#xD;
             intercourse (when it is in line with their preferred and usual lifestyle) or use 2&#xD;
             medically acceptable, highly effective forms of contraception for the duration of the&#xD;
             study, and at least 30 days after discontinuing study drug.&#xD;
&#xD;
          7. Males with a partner of childbearing potential must use a condom for the duration of&#xD;
             treatment and for at least 48 hours after discontinuing study drug.&#xD;
&#xD;
          8. In the opinion of the Investigator, the subject is able to communicate effectively&#xD;
             with study personnel, and is considered reliable, willing, and likely to be&#xD;
             cooperative with protocol requirements, including attending all study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is pregnant or lactating.&#xD;
&#xD;
          2. Subject has primary obstructive airway physiology: FEV1/FVC &lt;0.70 at Screening.&#xD;
&#xD;
          3. The subject has shown intolerance or significant lack of efficacy to a prostacyclin or&#xD;
             prostacyclin analogue that resulted in discontinuation or inability to effectively&#xD;
             titrate that therapy.&#xD;
&#xD;
          4. The subject has received any PAH-approved therapy, including prostacyclin therapy&#xD;
             (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity&#xD;
             testing), IP receptor agonists (selexipag), endothelin receptor antagonists,&#xD;
             phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase&#xD;
             stimulators within 60 days prior to Baseline. As needed use of a PDE5-I for erectile&#xD;
             dysfunction is permitted, provided no doses are taken within 48 hours of any&#xD;
             study-related efficacy assessments.&#xD;
&#xD;
          5. Use of any of the following medications: azathioprine (AZA), cyclosporine,&#xD;
             mycophenolate mofetil, tacrolimus, oral corticosteroids (OCS) &gt;20 mg/day or the&#xD;
             combination of OCS+AZA+N-acetylcysteine within 30 days prior to Baseline;&#xD;
             cyclophosphamide within 60 days prior to Baseline; or rituximab within 6 months prior&#xD;
             to Baseline.&#xD;
&#xD;
          6. The subject is receiving &gt;10 L/min of oxygen supplementation by any mode of delivery&#xD;
             at rest at Baseline.&#xD;
&#xD;
          7. Exacerbation of IPF or active pulmonary or upper respiratory infection within 30 days&#xD;
             prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for&#xD;
             treatment of the infection or acute exacerbation more than 30 days prior to Baseline&#xD;
             to be eligible. If hospitalized for an acute exacerbation of IPF or a pulmonary or&#xD;
             upper respiratory infection, subjects must have been discharged more than 90 days&#xD;
             prior to Baseline to be eligible.&#xD;
&#xD;
          8. Uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior&#xD;
             to Baseline or unstable angina within 30 days prior to Baseline.&#xD;
&#xD;
          9. In the opinion of the Investigator, the subject has any condition that would interfere&#xD;
             with the interpretation of study assessments or would impair study participation or&#xD;
             cooperation.&#xD;
&#xD;
         10. Use of any investigational drug/device or participation in any investigational study&#xD;
             in which the subject received a medical intervention (ie, procedure, device,&#xD;
             medication/supplement) within 30 days prior to Screening. Subjects participating in&#xD;
             non-interventional, observational, or registry studies are eligible.&#xD;
&#xD;
         11. Life expectancy &lt;6 months due to IPF or a concomitant illness.&#xD;
&#xD;
         12. Acute pulmonary embolism within 90 days prior to Baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>United Therapeutics Global Medical Information</last_name>
    <phone>919-485-8350</phone>
    <email>clinicaltrials@unither.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breeuh Ackerman</last_name>
      <phone>617-636-1334</phone>
    </contact>
    <contact_backup>
      <email>breeuh-research@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremy Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Sleep Allergy &amp; Lung Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariah Alexis</last_name>
      <phone>727-210-4606</phone>
      <email>malexis@stfrancismed.com</email>
    </contact>
    <investigator>
      <last_name>Francis Averill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Medical Group St. Vincent's Lung Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>33204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Topi</last_name>
      <phone>904-450-8647</phone>
      <email>kayla.vinson@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Abubakr Bajwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Disease Specialists, PA d/b/a PDS Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Yongue</last_name>
      <phone>407-624-4831</phone>
      <email>jyongue@pds-cfsc.com</email>
    </contact>
    <investigator>
      <last_name>Thomas O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Foust</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>135</phone_ext>
      <email>sfoust@cfpulmonary.com</email>
    </contact>
    <investigator>
      <last_name>Syed Mobin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Pulmonary &amp; Critical Care PLC</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karissa Dyar-Short</last_name>
      <phone>727-316-1176</phone>
      <email>karissa.dyar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eric Schilling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristal Monge</last_name>
      <phone>913-588-2473</phone>
      <email>chernandez@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sahil Pandya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hays</last_name>
      <phone>617-636-1334</phone>
      <email>mhays@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lung Research Center</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Shipp</last_name>
      <phone>314-682-3653</phone>
      <email>anna.shipp@stlukes-stl.com</email>
    </contact>
    <investigator>
      <last_name>Neil Ettinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J&amp;L Research, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>72032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Boucher</last_name>
      <phone>501-852-5500</phone>
      <email>cboucher@jlresearch.org</email>
    </contact>
    <investigator>
      <last_name>Ladley Abraham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinehurst Medical Clinic, Inc.</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Meyer</last_name>
      <phone>910-235-3144</phone>
      <email>Rmeyer@pinehurstmedical.com</email>
    </contact>
    <investigator>
      <last_name>Michael Pritchett, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Ingledue</last_name>
      <phone>513-558-0027</phone>
      <email>ingledra@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Nishant Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oregon Clinic, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Day</last_name>
      <phone>503-963-3182</phone>
      <email>mday@orclinic.com</email>
    </contact>
    <investigator>
      <last_name>Granthem Farr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center of Middle Tennessee</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>27067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Wallan</last_name>
      <phone>615-205-8350</phone>
      <email>jwallan@ctcmidtn.com</email>
    </contact>
    <investigator>
      <last_name>Aaron Milstone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Daniel</last_name>
      <phone>804-591-3533</phone>
      <email>bdaniel@paraccess.com</email>
    </contact>
    <investigator>
      <last_name>Shilpa Johri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treprostinil</keyword>
  <keyword>IPF</keyword>
  <keyword>ILD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

